{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:58:05Z","timestamp":1785380285563,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201300011C"],"award-info":[{"award-number":["HHSO100201300011C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.diagmicrobio.2026.117410","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T23:15:47Z","timestamp":1775690147000},"page":"117410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of different media and incubation times for determining the minimum inhibitory concentrations of gepotidacin, ciprofloxacin and ceftriaxone against Neisseria gonorrhoeae"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2885-6129","authenticated-orcid":false,"given":"Laura M.","family":"Koeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna","family":"DiFranco-Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Scangarella-Oman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2026.117410_bib0001","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117410_bib0002","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02047-16","article-title":"In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae","volume":"61","author":"Farrell","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117410_bib0003","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1093\/jac\/dky162","article-title":"In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae","volume":"73","author":"Jacobsson","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117410_bib0004","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117410_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01525-22","article-title":"Antimicrobial activity of Gepotidacin tested against Escherichia coli and Staphylococcus saprophyticus isolates causing urinary tract infections in medical centers worldwide (2019 to 2020)","volume":"67","author":"Arends","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"10428","key":"10.1016\/j.diagmicrobio.2026.117410_bib0006","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"issue":"10489","key":"10.1016\/j.diagmicrobio.2026.117410_bib0009","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.diagmicrobio.2026.117410_bib0010","series-title":"M07-A12 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard","year":"2024"},{"key":"10.1016\/j.diagmicrobio.2026.117410_bib0011","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12879-019-3900-z","article-title":"Ten years of external quality assessment (EQA) of Neisseria gonorrhoeae antimicrobial susceptibility testing in Europe elucidate high reliability of data","volume":"19","author":"Cole","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2026.117410_bib0012","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1093\/jac\/dkr332","article-title":"Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales","volume":"66","author":"Chisholm","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2026.117410_bib0013","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diagmicrobio.2016.04.016","article-title":"A comparison of agar dilution with the Calibrated Dichotomous Sensitivity (CDS) and Etest methods for determining the minimum inhibitory concentration of ceftriaxone against Neisseria gonorrhoeae","volume":"86","author":"Enriquez","year":"2016","journal-title":"Diag Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2026.117410_bib0014","unstructured":"Public Health England. 2025 GRASP report: data to September 2025 Accessed April 2026. https:\/\/www.gov.uk\/government\/publications\/gonococcal-resistance-to-antimicrobials-surveillance-programme-grasp-report\/grasp-report-data-to-september-2025. 2025."},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117410_bib0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W","article-title":"Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects","volume":"16","author":"Gootz","year":"1996","journal-title":"Med Res Rev"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117410_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections Treatment Guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2026.117410_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2026.117410_bib0018","series-title":"M07-A11 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard","year":"2018"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889326001604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889326001604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:02:34Z","timestamp":1785376954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889326001604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0732889326001604"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117410","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of different media and incubation times for determining the minimum inhibitory concentrations of gepotidacin, ciprofloxacin and ceftriaxone against Neisseria gonorrhoeae","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117410"}}